Company Interview / The small cap tackling inflammatory diseases

Gisela Mautner from Noxopharm (ASX: NOX) discusses their Heracles clinical trial, which just gained ethics approval in Australia. This milestone enables the first-in-human trial of their novel drug candidate, Soft Skin, aimed at treating chronic inflammatory diseases like skin lupus.

The trial, fully conducted in Australia, involves site initiation, staff training, and manufacturing finalisation. Gisela shares that the trial's dosing phase will likely extend until year's end, with substantial support from the R&D tax credit.

Funding for Noxopharm (ASX: NOX) is secured through sophisticated investors, bolstering their financial position. Soft Skin stands as their primary product, with potential applications for other diseases such as psoriasis and atopic dermatitis.